KANEKA
19.1.2023 04:57:38 CET | Business Wire | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has decided to increase its GMP*1 manufacturing capacity for mRNA*2 in Kaneka Eurogentec S.A. (Headquarters: Liège, Belgium; President: Lieven Janssens), a wholly owned group company in Europe. We plan to start operation sequentially from the end of 2023 with a capital investment of 2 billion JPY and a production capacity that is around 5 times higher than the current capacity. Kaneka Eurogentec S.A. will grow as a leading company of biopharmaceutical CDMO*3, responding to the vigorous global demand for mRNA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230118006042/en/
Kaneka Eurogentec S.A. building (Photo: Business Wire)
mRNA, which has been rapidly implemented in vaccines against COVID-19, is expected to be applied not only to vaccines for other infectious diseases but also to therapeutics for genetic diseases, cancer and so on. The demand for GMP manufacturing of mRNA will increase drastically with the active development of biopharmaceutical pipelines by pharmaceutical companies worldwide.
Kaneka Eurogentec S.A. is a CDMO for biopharmaceuticals inspected by the US FDA*4 and has world-class technology for producing plasmid DNA*5 and GMP manufacturing track records of over 25 years. They provide plasmid DNA, recombinant proteins, oligonucleotide*6 and so on as drug substances for pharmaceutical companies worldwide. In addition, Kaneka Eurogentec S.A. has started GMP manufacturing services for mRNA since 2020, and this capacity expansion will be utilized to expand the CDMO business.
Regarding the priority area of Health Care, Kaneka will continue to provide solutions globally for health issues through the growth of its biopharmaceutical business.
*1. |
GMP (Good Manufacturing Practice): A system for ensuring that products are consistently produced and controlled according to quality standards. |
*2. |
mRNA: An RNA molecule that is transcribed genetic information of protein synthesis from DNA. It is expected to be used as vaccines and therapeutics. |
*3. |
CDMO: Contract Development and Manufacturing Organization. |
*4. |
Food and Drug Administration (FDA): US governmental agency dealing with approval and supervision of violation of products which may be used by consumers in their daily life such as pharmaceutical products, cosmetics, medical devices, veterinary drugs and toys. |
*5. |
plasmid DNA: A general term for circular DNA molecules that exist outside the nucleus of bacteria such as E. coli and yeast, and that are passed down to daughter cells through cell division. |
|
It is conventionally used in processes for producing biopharmaceuticals such as therapeutic proteins and has been applied to genetic medicines and vaccines in recent years. |
*6. |
Oligonucleotide: Short polymeric sequences of nucleotides (RNA or DNA). It is used as drug substance of nucleic acid therapeutics. |
[General description of Kaneka Eurogentec S.A.]
Headquarters: Liège, Belgium
President: Lieven Janssens
Description of business: Manufacturing and sales of proteins, nucleic acids and peptides for medicinal, diagnostic and basic research uses
Established: 1985
Capital: 31 million euros
URL: http://www.eurogentec.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118006042/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead29.1.2026 07:37:00 CET | Press release
Year-to-Date Revenue Declined by 2.8% at Constant Exchange Rate (CER), 3.3% atActual Exchange Rates (AER);Impact of VYVANSE® Generics is Tapering OffCore Operating Profit Declined by 3.4% at both CER and AER Year to DateReported Operating Profit Increased by 1.2% at AER Year to Date, Lower Restructuring Expenses More Than Offset Impairment Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). The gap between incremental Growth & Launch Products revenue and VYVANSE erosion is narrowing, and operational efficiencies drove year-on-year reductions in operating expenses, including R&D. The company raised its full-year forecasts based on cost discipline and FX tailwind, while its Revenue Management Guidance has been updated primarily due to the impact of VYVANSE generics. Takeda is positioned for long-term growth and has multiple late-stage programs with multibillion-dollar peak revenue potential. Follow
Galderma Unveils ‘Wake Up To Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty29.1.2026 07:00:00 CET | Press release
‘Wake Up To Restylane®’ is a global campaign designed to meet the rising demand for natural-looking always-on results, helping people wake up looking refreshed and rested, and reframes Restylane treatments from a clinical procedure into an always-on beauty regimen Backed by 30 years of science, the Restylane portfolio is the only hyaluronic acid (HA) range offering four distinct technologies, designed to deliver personalized natural-looking outcomes that provide contour, definition, and hydration, with HA closest to the skin’s own1-7 This launch builds on new clinical data presented at the International Master Course on Aging Science (IMCAS) World Congress 2026, confirming Restylane’s proven efficacy and versatility across multiple facial areas and the décolletage8-11 Galderma (SIX: GALD), the pure-play dermatology category leader, has launched ‘Wake Up To Restylane’, a global campaign that showcases Restylane as an everyday beauty ally. Aligned with the growing desire for effortless,
Ubitus Partners with Maizuru City, Kyoto to Launch AI Data Center Project, Advancing the Deployment of a Top-Tier AI GPU Center in Japan29.1.2026 07:00:00 CET | Press release
Ubitus K.K. (Headquarters: Shinjuku, Tokyo; Representative Director & CEO: Wesley Kuo), a global leader in cloud streaming and AI solutions, today announced that it will hold a land signing ceremony and press conference with Maizuru City, Kyoto Prefecture, on January 29, 2026. At the event, Ubitus will officially unveil its comprehensive plan to construct an AI Data Center in Maizuru City, marking the company’s transition into the physical construction phase of its initiative to build a top-tier AI GPU center in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128944842/en/ Ubitus will launch its Maizuru City AI Data Center project on January 29, marking the first step toward building a top-tier AI GPU center in Japan. Powered by NVIDIA Blackwell GPUs and NeoCloud, the project strengthens Japan’s AI infrastructure and regional development. This land agreement represents the first major milestone following Ubitus’ sel
Lattice to Showcase Advanced Edge AI Solutions at the FPGA-forum 202628.1.2026 22:00:00 CET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its exhibition plan for the upcoming FPGA-forum 2026 taking place February 11 – 12, 2026 in Trondheim, Norway. As part of the event, Lattice Corporate Vice President of Software Solutions and Applications Engineering Eleena Ong will deliver a keynote presentation exploring how rapidly maturing AI technologies can turn FPGA platforms into innovation canvases for a much broader range of developers, sparking new application possibilities. Lattice will also deliver a technical presentation and host a demo showcase focused on how its low power FPGA solutions are advancing connectivity and edge AI applications. Who: Lattice Semiconductor What / When (GMT+1): Lattice Demo Showcase (Table #3), Feb 11-12 Keynote Feb. 11, 9:30 a.m. “Unlocking the Next Wave of FPGA Innovators with Generative and Agentic AI” Technical Presentation Feb. 12, 10 a.m. “Smaller. Cooler. Smarter: Lattice FPGAs’ Path to Uncompromised
Egon Zehnder Elects German Herrera as New Chair28.1.2026 20:01:00 CET | Press release
Herrera succeeds Michael Ensser, who will remain an active member of the Firm after his term in a planned transition. Egon Zehnder, the world’s premier leadership advisory firm, today announced that, in accordance with its established governance and three-year election cycle, German Herrera has been elected as the Firm’s next Chair by its worldwide partnership. Herrera will assume the role effective March 1, 2026. He will succeed Michael Ensser, who has held the position since 2022, in a planned succession at the conclusion of his regular term. Herrera joined the Firm in 1998 in Bogotá and has helped shape the Firm’s global presence, taking on a broad range of leadership roles, from co-leading the Global Family Business Advisory Practice to serving on the Executive Committee and the Market Council. Most recently, Herrera has guided Egon Zehnder’s U.S. market through a period of impressive growth and transformation, which today includes 15 offices and more than 150 consultants. As the f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom